Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin Lymphoma (HL) at Children's Oncology Group (COG) Institutions

Sharon M. Castellino, MD MSc, Angela Punnett, MD, Susan K Parsons, MD MRP, Nicholas P. DeGroote, MPH, Sally Muehle, Hongli Li, MS, Michael E. Roth, MD, Alex F. Herrera, MD, Jonathan W. Friedberg, MD MSSc, Nita L. Seibel, MD, Kara M. Kelly, MD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-134738

Published: 2020

Journal Articles

ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression

Jun J. Yang, PhD, Heng Xu, PhD, Deepa Bhojwani, Takaya Moriyama, MD, Maoxiang Qian, PhD, Xue Yang, Nita L. Seibel, MD, Mary V. Relling, PharmD, William L. Carroll, MD, Ching-Hon Pui, MD, William E. Evans, PharmD

Blood (2014) 124 (21): 791.

https://doi.org/10.1182/blood.V124.21.791.791

Published: 2014

Journal Articles

PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia

Blood (2012) 120 (21): 530.

https://doi.org/10.1182/blood.V120.21.530.530

Published: 2012

Journal Articles

Extremes of Weight Are Associated with Increased Treatment-Related Toxicity in High-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group,

Etan Orgel, MD, Richard Sposto, Ph.D., Jemily Malvar, M.S., Nita L. Seibel, MD, Elena J. Ladas, MS, RD, Paul Gaynon, MD, David R. Freyer, DO, MS

Blood (2011) 118 (21): 3574.

https://doi.org/10.1182/blood.V118.21.3574.3574

Published: 2011

Journal Articles

Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group

David R. Freyer, Meenakshi Devidas, Mei La, William L. Carroll, Paul S. Gaynon, Stephen P. Hunger, Nita L. Seibel

Blood (2011) 117 (11): 3010–3015.

https://doi.org/10.1182/blood-2010-07-294678

Published: 2011

Includes: Supplemental data

Journal Articles

Longer Time to the Start of Continuation Therapy Is Associated with Improved Survival In High Risk Pediatric Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG)

Marla H Daves, MD, Stephen Hunger, MD, Stephen B Linda, MS, W. Paul Bowman, MD, Nita L. Seibel, MD, Lillian Sung, MD, PhD, Meenakshi Devidas, PhD

Blood (2010) 116 (21): 3223.

https://doi.org/10.1182/blood.V116.21.3223.3223

Published: 2010

Journal Articles

Adverse Reactions to PEG and Erwinia Asparaginase and Correlation with Anti-Asparaginase Antibody Data and Survival in Children with Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group Study CCG 1961.

Girish Dhall, M.D., Tamekia Jones, PhD, David Radvinsky, Nathan Robison, MD, Anna Butturini, MD, Joan I Rubin, RN, Paul S. Gaynon, MD, Eduard H Panosyan, MD, Ioannis A Avramis, Vassilios I Avramis, PhD, Lawrence J. Ettinger, MD, Nita L. Seibel, MD

Blood (2009) 114 (22): 3077.

https://doi.org/10.1182/blood.V114.22.3077.3077

Published: 2009

Journal Articles

Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Is Independent of Prior Treatment Intensity: A Report from the Children’s Oncology Group (COG).

David Robert Freyer, DO, Nita L. Seibel, MD, Mei K La, MS, Meenakshi Devidas, PhD, William L. Carroll, MD, Stephen P. Hunger, MD, Paul S. Gaynon, MD

Blood (2008) 112 (11): 917.

https://doi.org/10.1182/blood.V112.11.917.917

Published: 2008

Journal Articles

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Nita L. Seibel, Peter G. Steinherz, Harland N. Sather, James B. Nachman, Cynthia DeLaat, Lawrence J. Ettinger, David R. Freyer, Leonard A. Mattano, Jr, Caroline A. Hastings, Charles M. Rubin, Kathy Bertolone, Janet L. Franklin, Nyla A. Heerema, Torrey L. Mitchell, Allan F. Pyesmany, Mei K. La, Cheryl Edens, Paul S. Gaynon

Blood (2008) 111 (5): 2548–2555.

https://doi.org/10.1182/blood-2007-02-070342

Published: 2008

Journal Articles

Outcomes for B-Precursor Patients in Legacy Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.

Paul S. Gaynon, MD, Bruce C. Camitta, MD, Yousif Matloub, MD, Paul L. Martin, MD, Naomi Winick, MD, Nita L. Seibel, MD, W. Paul Bowman, MD, Harland N. Sather, PhD, Meenakshi Devidas, PhD, Stephen Hunger, MD, William L. Carroll, MD

Blood (2007) 110 (11): 847.

https://doi.org/10.1182/blood.V110.11.847.847

Published: 2007

Journal Articles

Assessment of Anti-Asparaginase (ASNase) Antibodies (Ab) and ASNase Activity after Suspected Clinical Allergy.

Prakash N. Tiwari, MD, Monica Zielinski, MS, John J. Quinn, MD, Stuart E. Siegel, MD, Paul S. Gaynon, MD, Peter Wakamatsu, MPH, Nita L. Seibel, MD, Vassilios I. Avramis, PhD

Blood (2006) 108 (11): 1878.

https://doi.org/10.1182/blood.V108.11.1878.1878

Published: 2006

Journal Articles

Outcomes in Children and Adolescents with a Markedly Elevated White Blood Cell Count (>200,000) at Diagnosis of High Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group.

Caroline Hastings, MD, Harland N. Sather, PhD, Nita L. Seibel, MD, James Nachman, MD, Peter G. Steinherz, MD, Kathy Bertolone, FNP, Cynthia DeLaat, MD, Lawrence J. Ettinger, MD, Janet Franklin, MD, David Robert Freyer, DO, Leonard A. Mattano, MD, Torrey L. Mitchell, MD, Charles M. Rubin, MD, Allan F. Pyesmany, MD, Nyla A. Heerema, PhD, Cheryl Edens, Paul S. Gaynon, MD

Blood (2006) 108 (11): 1870.

https://doi.org/10.1182/blood.V108.11.1870.1870

Published: 2006

Journal Articles

Outcomes in CCG-2961, a Children’s Cancer Group Phase III Trial for Untreated Acute Myeloid Leukemia (AML).

Beverly J. Lange, MD, Franklin O. Smith, MD, Patricia A. Dinndorf, MD, Carola A.S. Arndt, MD, Dorothy R. Barnard, MD, Kathryn Dusenbery, MD, Steven A. Feig, MD, James H. Feusner, MD, Sandra Luna-Fineman, MD, Joseph Neglia, MD, MPH, Nita L. Seibel, MD, Leonard Sender, MD, Kevin M. Shannon, MD, Margie Weiman, RN, Robert B. Gerbing, MA, Todd A. Alonzo, PhD

Blood (2005) 106 (11): 169.

https://doi.org/10.1182/blood.V106.11.169.169

Published: 2005

Journal Articles

Gene Signatures Predictive of Outcome in Higher Risk Childhood Acute Lymphoblastic Leukemia (ALL).

Naomi P. Moskowitz, MD, Deepa Bhojwani, MD, Huining Kang, PhD, Dong-Joon Min, PhD, Jeffrey Potter, PhD, Richard Harvey, PhD, Nita L. Seibel, MD, Elizabeth Raetz, MD, Harland N. Sather, PhD, Stephen P. Hunger, MD, Cheryl L. Willman, MD, William L. Carroll, MD

Blood (2005) 106 (11): 1449.

https://doi.org/10.1182/blood.V106.11.1449.1449

Published: 2005

Journal Articles

Pharmacokinetics and Pharmacodynamics of Three Asparaginases in Pediatric Patients with Higher Risk Acute Lymphoblastic Leukemia: A Report from CCG-1961.

Eduard H. Panosyan, M.D., Nita L. Seibel, M.D., Rita S. Grigoryan, M.D., Ioannis A. Avramis, B.S., Jon D. Jaques, Lawrence J. Ettinger, M.D., Paul S. Gaynon, M.D., Harland N. Sather, Ph.D., Janet Franklin, M.D., Fu Cecilia, M.D., Stuart E. Siegel, M.D., Howard J. Fingert, M.D., Vassilios I. Avramis, Ph.D.

Blood (2004) 104 (11): 2745.

https://doi.org/10.1182/blood.V104.11.2745.2745

Published: 2004

Journal Articles

Treatment of High Risk T-Cell Acute Lymphoblastic Leukemia (T-ALL): Comparison of Recent Experience of the Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG).

Nita L. Seibel, M.D., Barbara L. Asselin, M.D., James B. Nachman, M.D., Peter Steinherz, M.D., Bruce Camitta, M.D., Meenakshi Devidas, Ph.D., Harland N. Sather, Ph.D.

Blood (2004) 104 (11): 681.

https://doi.org/10.1182/blood.V104.11.681.681

Published: 2004

NARROW

Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin Lymphoma (HL) at Children's Oncology Group (COG) Institutions

ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression

PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia

Extremes of Weight Are Associated with Increased Treatment-Related Toxicity in High-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group,

Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group

Longer Time to the Start of Continuation Therapy Is Associated with Improved Survival In High Risk Pediatric Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG)

Adverse Reactions to PEG and Erwinia Asparaginase and Correlation with Anti-Asparaginase Antibody Data and Survival in Children with Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group Study CCG 1961.

Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Is Independent of Prior Treatment Intensity: A Report from the Children’s Oncology Group (COG).

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

Outcomes for B-Precursor Patients in Legacy Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report.

Assessment of Anti-Asparaginase (ASNase) Antibodies (Ab) and ASNase Activity after Suspected Clinical Allergy.

Outcomes in Children and Adolescents with a Markedly Elevated White Blood Cell Count (>200,000) at Diagnosis of High Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group.

Outcomes in CCG-2961, a Children’s Cancer Group Phase III Trial for Untreated Acute Myeloid Leukemia (AML).

Gene Signatures Predictive of Outcome in Higher Risk Childhood Acute Lymphoblastic Leukemia (ALL).

Pharmacokinetics and Pharmacodynamics of Three Asparaginases in Pediatric Patients with Higher Risk Acute Lymphoblastic Leukemia: A Report from CCG-1961.

Treatment of High Risk T-Cell Acute Lymphoblastic Leukemia (T-ALL): Comparison of Recent Experience of the Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only